Abstract:
PROBLEM TO BE SOLVED: To provide a perfect human antibody IL-18 as a preferred IL-18 inhibitor, because parts of a chimera and humanized antibodies still remain as a murine sequence, and therefore, may cause an undesirable immune reaction if they are administered over a long period.SOLUTION: The present invention includes an antigen binding to a human interleukin-18, particularly an antigen binding to an epitope of a human IL-18. The antibody can be, for example, an entirely human antibody, a recombinant antibody, or monoclonal antibody. A preferred antibody has the high affinity for the hIL-18, and/or neutralizes an hIL-18 activity in vitro and in vivo. The antibody can be of a full-length or an antigen binding portion thereof. The methods of making and using the antibody are also provided. The antibody, or the antibody portion is useful for detecting the hIL-18, and also useful, for example, for inhibiting a hIL-18 activity in a human subject suffering from a disorder in which the hIL-18 is detrimental.
Abstract:
PROBLEM TO BE SOLVED: To provide an antibody that binds with IL-12p40 binding protein, particularly human interleukin 12 (hIL-12) and/or human IL-23 (hIL-23), especially a chimera antibody, a CDR graft antibody and a humanized antibody.SOLUTION: A preferred antibody has a high affinity to hIL-12 and/or hIL-23, and neutralizes hIL-12 and/or hIL-23 activity in vitro and in vivo. The present antibody may be a full length antibody or an antigen binding part thereof. The present antibody or antibody part is useful for example to detect hIL-12 and/or hIL-23, and to inhibit hIL-12 and/or hIL-23 activity in human subject having a disorder harmfully caused by hIL-12 and/or hIL-23 activity.
Abstract:
PROBLEM TO BE SOLVED: To provide engineered multivalent and multispecific binding proteins, methods for making the proteins, and methods for using the proteins in the prevention and/or treatment of acute and chronic inflammatory and other diseases.SOLUTION: The binding protein comprises a polypeptide chain, wherein the polypeptide chain comprises VD1-(X1)-VD2-C-(X2), wherein VD1 is a first variable domain, VD2 is a second variable domain, C is a constant domain, X1 represents an amino acid or polypeptide, X2 represents an Fc region and n is 0 or 1.
Abstract:
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
Abstract:
The present invention relates to polypeptides which comprise the ligand binding domain of Lck, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Lck. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential selective inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain selectively.
Abstract:
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
Abstract:
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
Abstract:
The present invention is directed to novel imidazopyrazine and imidazopyrimidine compounds of formula (I), wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.
Abstract:
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.